Natco Pharma has invested $2 million in Cellogen Therapeutics

Natco Pharma has invested $2 million in Cellogen Therapeutics, marking a significant step in our mission to revolutionize healthcare. This strategic investment supports the development of advanced CAR T cell therapies and gene manipulation technologies, enabling us to address critical unmet needs in cancer and blood disorder treatments. With Natco’s expertise and Cellogen's innovative approach, we are poised to make a transformative impact on the future of medicine.